A review of 34 clinical trials on a popular drug to treat hair loss in men found that none of the studies adequately reported on sexual side effects, researchers said.
The findings raise serious questions about whether the drug – known as finasteride and marketed as Propecia and Proscar, among other names – is safe, said the report by scientists at Northwestern University, published in the Journal of the American Medical Association (JAMA) Dermatology
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Not one of the 34 published clinical trial reports provided adequate information about the severity, frequency or reversibility of sexual adverse effects.
The published clinical trial reports did not answer the key questions doctors and patients want to know:
1) How safe is finasteride? Specifically, what is the risk that a man taking finasteride will develop sexual dysfunction?
2) How severe is finasteride-associated sexual dysfunction when it happens to a man?
3) If a man gets sexual dysfunction while taking finasteride, will sexual function return to normal when the drug is stopped? What is the risk of persistent sexual dysfunction associated with taking finasteride?
Finasteride was originally developed to treat enlarged prostate (prostatic hyperplasia) in older men. Men who take the drug for male pattern hair loss are typically younger and take a dose of finasteride that is about one-fifth the dose used for prostatic hyperplasia.
“People who take or prescribe the drug assume it’s safe, but there is insufficient information to make that judgment, ” said lead study author Dr. Steven Belknap, research assistant professor of dermatology and general internal medicine at Northwestern University Feinberg School of Medicine.
“Our findings raise several questions, ” Belknap said. “Why do the published reports of these 34 clinical trials not provide adequate information about the severity and frequency of sexual toxicity? Was this information obtained but then not included in published articles? Or, were these clinical trials performed in a way that simply didn’t capture this essential information? And most importantly, is the risk to benefit ratio of finasteride acceptable?”
The study is a report from the RADAR (Research on Adverse Drug Events and Reports) project at Northwestern’s Feinberg School. The RADAR study points to a larger problem in the way clinical trials are performed and analyzed in meta-analyses.
“Typically, there is more focus on the desirable effects of the drug being studied compared to the toxic effects, ” Belknap said.
Among other key findings of the paper:
Of 5, 704 men in the Northwestern Medicine clinical data repository who were treated for male pattern baldness with finasteride, only 31 percent would meet inclusion criteria for the pivotal trials referenced in the manufacturer’s “Full Prescribing Information.”
Thus, the available information from clinical trials does not apply to most of these men in Northwestern’s study population who took finasteride for male pattern baldness. For example, some men with hair loss who are taking finasteride have diabetes mellitus, high blood pressure or are taking other drugs such as diuretics or antidepressants that also increase the risk of sexual dysfunction.
Duration of drug safety evaluation was limited to one year or less for 26 of 34 trials (76 percent.) But 33 percent of men in the Northwestern clinical data repository took finasteride for more than one year.
